Treatment of Immune Thrombocytopenia in Adults: The Role of Thrombopoietin-Receptor Agonists

Seminars in Hematology

Volumn 52, Issue 1, 2015, Pages 16-24

  Rodeghiero, Francesco ^a   Ruggeri, Marco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVATROMBOPAG; CORTICOSTEROID; CYTOKINE RECEPTOR AGONIST; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; PLACEBO; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADULT; ARTERY THROMBOSIS; BLEEDING; CATARACT; CONTUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; LOW DRUG DOSE; MEGAKARYOCYTE; MYELOFIBROSIS; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PREVALENCE; RECURRENCE FREE SURVIVAL; REMISSION; REVIEW; RHINOPHARYNGITIS; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; AGONISTS; CHRONIC DISEASE; HEMORRHAGE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ADULT; CHRONIC DISEASE; HEMORRHAGE; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; SPLENECTOMY;

EID: 84920689887     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.10.006     Document Type: Review

References (64)

1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
2. Stasi R., Evangelista M.L., Stipa E., Buccisano F., Venditti A., Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008, 99:4-13.
3. Gernsheimer T.B. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2008, 219-226.
4. Nugent D., McMillan R., Nichol J.L., Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009, 146:585-596.
5. Ballem P.J., Segal G.M., Stratton J.R., Gernsheimer T., Adamson J.W., Slichter S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80:33-40.
6. Frederiksen H., Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999, 94:909-913.
7. Neylon A.J., Saunders P.W., Howard M.R., Proctor S.J., Taylor P.R. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003, 122:966-974.
8. Schoonen W.M., Kucera G., Coalson J., et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009, 145:235-244.
9. Segal J.B., Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006, 4:2377-2383.
10. Feudjo-Tepie M.A., Robinson N.J., Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008, 6:711-712.
11. Landgren O., Gridley G., Fears T.R., Caporaso N. Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans. Blood 2006, 108:1111-1112.
12. Cines D.B., Bussel J.B., Liebman H.A., Luning Prak E.T. The ITP syndrome: pathogenic and clinical diversity. Blood 2009, 113:6511-6521.
13. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
14. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-596.
15. Cines D.B., Bussel J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005, 106:2244-2251.
16. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
17. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
18. Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104:2623-2634.
19. Boyle S., White R.H., Brunson A., Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013, 121:4782-4790.
20. Rodeghiero F., Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?. Br J Haematol 2012, 158:16-29.
21. Vianelli N., Palandri F., Polverelli N., et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013, 98:875-880.
22. Arnold D.M., Dentali F., Crowther M.A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
23. Godeau B., Porcher R., Fain O., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008, 112:999-1004.
24. Patel V.L., Mahevas M., Lee S.Y., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
25. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
26. Kuter D.J., Rummel M., Boccia R., et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010, 363:1889-1899.
27. Bussel J.B., Provan D., Shamsi T., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
28. Cheng G., Saleh M.N., Marcher C., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377:393-402.
29. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.
30. Gernsheimer T.B., George J.N., Aledort L.M., et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010, 8:1372-1382.
31. Kuter D.J., Bussel J.B., Newland A., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013, 161:411-423.
32. Saleh M.N., Bussel J.B., Cheng G., et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013, 121:537-545.
33. Rodeghiero F., Ruggeri M. Is splenectomy still the gold standard for the treatment of chronic ITP?. Am J Hematol 2008, 83:91.
34. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
35. Rodeghiero F., Ruggeri M. ITP and international guidelines: what do we know, what do we need?. Presse Med 2014, 43:e61-7.
36. Tomiyama Y., Miyakawa Y., Okamoto S., et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012, 10:799-806.
37. Bussel J.B., Kuter D.J., Aledort L.M., et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014, 123:3887-3894.
38. Rodeghiero F., Stasi R., Giagounidis A., et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol 2013, 91:423-436.
39. Khellaf M., Michel M., Quittet P., et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011, 118:4338-4345.
40. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128-1132.
41. Ruggeri M., Tosetto A., Palandri F., et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014, 12:1266-1273.
42. Kuter D.J., Mathias S.D., Rummel M., et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol 2012, 87:558-561.
43. Zeng Y., Duan X., Xu J., Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011, (7). CD008235.
44. Rodeghiero F. TPO-receptor agonists in ITP: a clinician[U+05F3]s navigation between Scylla and Charybdis. Am J Hematol 2012, 87:943.
45. Pignatti F., Flores B., Jonsson B. Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective. Am J Hematol 2012, 87:943-944.
46. Arnold D.M. Platelet count or bleeding as the outcome in ITP trials?. Am J Hematol 2012, 87:945-946.
47. Ruggeri M. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician[U+05F3]s perspective. Am J Hematol 2012, 87:946-947.
48. Rodeghiero F., Michel M., Gernsheimer T., et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013, 121:2596-2606.
49. Scaramucci L., Giovannini M., Niscola P., Tendas A., Perrotti A., De Fabritiis P. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus 2014, 21:1-3.
50. Polverelli N., Palandri F., Iacobucci I., Catani L., Martinelli G., Vianelli N. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms. Br J Haematol 2013, 161:142-144.
51. D'Arena G., Guariglia R., Mansueto G., et al. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood 2013, 121:1240-1242.
52. Khellaf M., Viallard J.F., Hamidou M., et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013, 98:881-887.
53. Mahevas M., Fain O., Ebbo M., et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 2014, 165:865-869.
54. Ghadaki B., Nazi I., Kelton J.G., Arnold D.M. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013, 53:2807-2812.
55. Bao W., Bussel J.B., Heck S., et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010, 116:4639-4645.
56. Sailer T., Lechner K., Panzer S., Kyrle P.A., Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006, 91:1041-1045.
57. Gudbrandsdottir S., Birgens H.S., Frederiksen H., et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013, 121:1976-1981.
58. Gomez-Almaguer D., Herrera-Rojas M.A., Jaime-Perez J.C., et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood 2014, 123:3906-3908.
59. Visco C., Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin North Am 2009, 23:1261-1274.
60. Olnes M.J., Scheinberg P., Calvo K.R., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012, 367:11-19.
61. Newland A., Caulier M.T., Kappers-Klunne M., et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006, 135:547-553.
62. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006, 355:1672-1681.
63. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
64. Bussel J.B., Saleh M.N., Vasey S.Y., Mayer B., Arning M., Stone N.L. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol 2013, 160:538-546.